Dayvigo®
(lemborexant)

Digital Adherence Program

Program overview

This sponsored program aims to provide education and support to patients prescribed Dayvigo for the treatment of insomnia.

Patients will receive a series of 4 messages over 2 weeks aimed at improving their quality use of medicines, medication adherence and treatment outcomes.

When?

This program was launched in July 2022.

For which patients?

Messages will be delivered via the app and SMS to patients currently prescribed Dayvigo. 

Click here to view a sample of the messages

Dayvigo-1